We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Proteomic Testing May Enable NIV Diagnosis of Respiratory Pathologies in Preterm Newborns

By LabMedica International staff writers
Posted on 19 Sep 2016
A team of researchers is developing its new method for noninvasive diagnosis and therapeutic response monitoring of conditions in preterm newborns based on marker sets now identified by proteome analysis of urine samples.

The majority of patients in neonatal intensive care units are premature babies, who often have respiratory conditions. More...
It is important to distinguish whether their illness is due to infection or a failure in the developmental process. The composition of biological fluids (e.g. blood, urine, saliva) is highly complex, and most current diagnostic procedures for neonatal intensive therapy include sample collections that are invasive (e.g. biopsy) or semi-invasive (e.g. blood sampling).

Using high-performance mass spectrometry (HPMS; more specifically LC-MS/MS), experts from the Moscow Institute of Physics and Technology (MIPT; Moscow, Russia) are identifying different proteins and determining their concentrations in target fluids. Studies of the urinary proteome in pediatrics, especially in neonatology, are limited. In the new study, the team investigated the urine proteome of preterm newborns with respiratory pathologies. In order to further specify the defined infant-specific dataset, proteins were compared with the urinary proteome of healthy adults (men and pregnant women).

As a result bioinformatic processing of the HPMS data, the team singled out 36 proteins that indicate if respiratory pathologies are infectious (congenital pneumonia) or non-infectious (tachypnea, infant respiratory distress syndrome).

“In our pilot study, we succeeded in defining the core urinary proteome and proteins specific for infants and pathological conditions. We are pioneers in the non-invasive identification of urinary biomarkers diagnosing respiratory conditions in newborns. The results are optimistic and will serve as a platform to move forward in developing a method of monitoring conditions in newborns,” said team leader Prof. Evgeny Nikolaev, head of MIPT’s Laboratory of Ionic and Molecular Physics.

The study, by Starodubtseva NL, Kononikhin AS, et al, was published June 14, 2016, online ahead of print in the Journal of Proteomics.

Related Links:
Moscow Institute of Physics and Technology


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.